Does the media refer more to ALMR or CTKB?

In the previous week, Alamar Biosciences had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 4 mentions for Alamar Biosciences and 2 mentions for Cytek Biosciences. Alamar Biosciences' average media sentiment score of 0.42 beat Cytek Biosciences' score of 0.10 indicating that Alamar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytek Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CTKB or MRVI?

In the previous week, Maravai LifeSciences had 5 more articles in the media than Cytek Biosciences. MarketBeat recorded 7 mentions for Maravai LifeSciences and 2 mentions for Cytek Biosciences. Maravai LifeSciences' average media sentiment score of 0.58 beat Cytek Biosciences' score of 0.10 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BLFS or CTKB?

In the previous week, BioLife Solutions had 3 more articles in the media than Cytek Biosciences. MarketBeat recorded 5 mentions for BioLife Solutions and 2 mentions for Cytek Biosciences. BioLife Solutions' average media sentiment score of 0.75 beat Cytek Biosciences' score of 0.10 indicating that BioLife Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytek Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to FTRE or CTKB?

In the previous week, Fortrea had 7 more articles in the media than Cytek Biosciences. MarketBeat recorded 9 mentions for Fortrea and 2 mentions for Cytek Biosciences. Fortrea's average media sentiment score of 0.33 beat Cytek Biosciences' score of 0.10 indicating that Fortrea is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cytek Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CTKB or PSNL?

In the previous week, Personalis had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Personalis and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.10 beat Personalis' score of 0.05 indicating that Cytek Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Personalis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cytek Biosciences (CTKB) Competitors

$5.36 +0.02 (+0.37%)

Closing price 04:00 PM Eastern

Extended Trading

$5.43 +0.07 (+1.31%)

As of 04:43 PM Eastern

Compare

CTKB vs. ALMR, MRVI, BLFS, FTRE, and PSNL

Should you buy Cytek Biosciences stock or one of its competitors? Cytek Biosciences's main competitors and comparable companies include Alamar Biosciences (ALMR), Maravai LifeSciences (MRVI), BioLife Solutions (BLFS), Fortrea (FTRE), and Personalis (PSNL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Cytek Biosciences compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Cytek Biosciences (NASDAQ:CTKB) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, Alamar Biosciences had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 4 mentions for Alamar Biosciences and 2 mentions for Cytek Biosciences. Alamar Biosciences' average media sentiment score of 0.42 beat Cytek Biosciences' score of 0.10 indicating that Alamar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alamar Biosciences presently has a consensus target price of $31.80, suggesting a potential upside of 14.51%. Cytek Biosciences has a consensus target price of $5.56, suggesting a potential upside of 4.17%. Given Alamar Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alamar Biosciences is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Alamar Biosciences has higher earnings, but lower revenue than Cytek Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	25.97	-$29.82M	-$1.96	N/A
Cytek Biosciences	$201.49M	3.44	-$66.54M	-$0.62	N/A

Alamar Biosciences has a net margin of 0.00% compared to Cytek Biosciences' net margin of -38.98%. Alamar Biosciences' return on equity of 0.00% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Cytek Biosciences	-38.98%	-12.40%	-9.17%

69.5% of Cytek Biosciences shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Alamar Biosciences beats Cytek Biosciences on 10 of the 15 factors compared between the two stocks.

How does Cytek Biosciences compare to Maravai LifeSciences?

Cytek Biosciences (NASDAQ:CTKB) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Maravai LifeSciences had 5 more articles in the media than Cytek Biosciences. MarketBeat recorded 7 mentions for Maravai LifeSciences and 2 mentions for Cytek Biosciences. Maravai LifeSciences' average media sentiment score of 0.58 beat Cytek Biosciences' score of 0.10 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytek Biosciences has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.44	-$66.54M	-$0.62	N/A
Maravai LifeSciences	$185.74M	10.39	-$130.77M	-$0.52	N/A

Maravai LifeSciences has a net margin of -37.07% compared to Cytek Biosciences' net margin of -38.98%. Cytek Biosciences' return on equity of -12.40% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

Cytek Biosciences has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Cytek Biosciences currently has a consensus target price of $5.56, suggesting a potential upside of 4.17%. Maravai LifeSciences has a consensus target price of $7.38, suggesting a potential downside of 0.74%. Given Cytek Biosciences' higher probable upside, equities research analysts plainly believe Cytek Biosciences is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Cytek Biosciences beats Maravai LifeSciences on 9 of the 17 factors compared between the two stocks.

How does Cytek Biosciences compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioLife Solutions has a net margin of 53.29% compared to Cytek Biosciences' net margin of -38.98%. BioLife Solutions' return on equity of 2.70% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
Cytek Biosciences	-38.98%	-12.40%	-9.17%

BioLife Solutions has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

In the previous week, BioLife Solutions had 3 more articles in the media than Cytek Biosciences. MarketBeat recorded 5 mentions for BioLife Solutions and 2 mentions for Cytek Biosciences. BioLife Solutions' average media sentiment score of 0.75 beat Cytek Biosciences' score of 0.10 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioLife Solutions has higher earnings, but lower revenue than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	19.63	-$4.59M	$1.16	33.28
Cytek Biosciences	$201.49M	3.44	-$66.54M	-$0.62	N/A

BioLife Solutions currently has a consensus target price of $31.38, suggesting a potential downside of 18.74%. Cytek Biosciences has a consensus target price of $5.56, suggesting a potential upside of 4.17%. Given Cytek Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	0 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.09
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

BioLife Solutions beats Cytek Biosciences on 11 of the 16 factors compared between the two stocks.

How does Cytek Biosciences compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Cytek Biosciences has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.72B	0.72	-$986.20M	-$0.91	N/A
Cytek Biosciences	$201.49M	3.44	-$66.54M	-$0.62	N/A

In the previous week, Fortrea had 7 more articles in the media than Cytek Biosciences. MarketBeat recorded 9 mentions for Fortrea and 2 mentions for Cytek Biosciences. Fortrea's average media sentiment score of 0.33 beat Cytek Biosciences' score of 0.10 indicating that Fortrea is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

69.5% of Cytek Biosciences shares are held by institutional investors. 0.7% of Fortrea shares are held by insiders. Comparatively, 10.4% of Cytek Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Fortrea has a net margin of -3.18% compared to Cytek Biosciences' net margin of -38.98%. Fortrea's return on equity of 10.72% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Cytek Biosciences	-38.98%	-12.40%	-9.17%

Fortrea presently has a consensus target price of $22.10, indicating a potential upside of 7.49%. Cytek Biosciences has a consensus target price of $5.56, indicating a potential upside of 4.17%. Given Fortrea's stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortrea is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Fortrea has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

Summary

Fortrea beats Cytek Biosciences on 10 of the 16 factors compared between the two stocks.

How does Cytek Biosciences compare to Personalis?

Cytek Biosciences (NASDAQ:CTKB) and Personalis (NASDAQ:PSNL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Cytek Biosciences has a net margin of -38.98% compared to Personalis' net margin of -153.84%. Cytek Biosciences' return on equity of -12.40% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
Personalis	-153.84%	-46.47%	-35.30%

In the previous week, Personalis had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Personalis and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.10 beat Personalis' score of 0.05 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Personalis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by company insiders. Comparatively, 4.2% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cytek Biosciences has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.44	-$66.54M	-$0.62	N/A
Personalis	$69.65M	24.06	-$81.27M	-$1.09	N/A

Cytek Biosciences has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Personalis has a beta of 2.32, indicating that its share price is 132% more volatile than the broader market.

Cytek Biosciences presently has a consensus target price of $5.56, indicating a potential upside of 4.17%. Personalis has a consensus target price of $14.54, indicating a potential downside of 9.15%. Given Cytek Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cytek Biosciences is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Personalis	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Summary

Cytek Biosciences beats Personalis on 12 of the 15 factors compared between the two stocks.

Get Cytek Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTKB vs. The Competition

Export

Metric	Cytek Biosciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$696.69M	$10.42B	$7.14B	$13.21B
Dividend Yield	N/A	1.44%	2.53%	16.47%
P/E Ratio	-8.65	31.67	275.15	25.94
Price / Sales	3.46	105.99	566.78	83.59
Price / Cash	N/A	27.56	77.41	52.81
Price / Book	2.01	6.36	10.80	6.27
Net Income	-$66.54M	$56.67B	$3.50B	$382.13M
7 Day Performance	-7.75%	-1.74%	-2.02%	-1.39%
1 Month Performance	16.02%	5.87%	-7.54%	-5.62%
1 Year Performance	37.44%	27.13%	3.31%	-1.54%

Cytek Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTKB Cytek Biosciences	1.0226 of 5 stars	$5.36 +0.4%	$5.56 +3.8%	+40.9%	$696.69M	$201.49M	N/A	702
ALMR Alamar Biosciences	3.1628 of 5 stars	$32.65 +0.1%	$31.80 -2.6%	N/A	$2.26B	$74.21M	N/A	222	News Coverage High Trading Volume
MRVI Maravai LifeSciences	1.5702 of 5 stars	$7.65 +0.3%	$6.83 -10.7%	+124.5%	$1.98B	$185.74M	N/A	415	Analyst Upgrade
BLFS BioLife Solutions	2.5997 of 5 stars	$39.22 +0.2%	$31.38 -20.0%	N/A	$1.92B	$96.21M	33.81	155
FTRE Fortrea	2.8038 of 5 stars	$19.74 -1.6%	$22.00 +11.4%	+120.8%	$1.91B	$2.72B	N/A	14,300	Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTKB) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytek Biosciences (CTKB) Competitors

CTKB vs. ALMR, MRVI, BLFS, FTRE, and PSNL

How does Cytek Biosciences compare to Alamar Biosciences?

Summary

How does Cytek Biosciences compare to Maravai LifeSciences?

Summary

How does Cytek Biosciences compare to BioLife Solutions?

Summary

How does Cytek Biosciences compare to Fortrea?

Summary

How does Cytek Biosciences compare to Personalis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytek Biosciences (CTKB) Competitors

CTKB vs. ALMR, MRVI, BLFS, FTRE, and PSNL

How does Cytek Biosciences compare to Alamar Biosciences?

Does the media refer more to ALMR or CTKB?

Do analysts rate ALMR or CTKB?

Which has preferable valuation and earnings, ALMR or CTKB?

Is ALMR or CTKB more profitable?

Do insiders & institutionals believe in ALMR or CTKB?

Summary

How does Cytek Biosciences compare to Maravai LifeSciences?

Do insiders & institutionals hold more shares of CTKB or MRVI?

Does the media prefer CTKB or MRVI?

Which has stronger earnings & valuation, CTKB or MRVI?

Is CTKB or MRVI more profitable?

Which has more volatility & risk, CTKB or MRVI?

Do analysts recommend CTKB or MRVI?

Summary

How does Cytek Biosciences compare to BioLife Solutions?

Do institutionals & insiders hold more shares of BLFS or CTKB?

Is BLFS or CTKB more profitable?

Which has more risk & volatility, BLFS or CTKB?

Does the media favor BLFS or CTKB?

Which has higher valuation and earnings, BLFS or CTKB?

Do analysts recommend BLFS or CTKB?

Summary

How does Cytek Biosciences compare to Fortrea?

Which has higher valuation & earnings, FTRE or CTKB?

Does the media refer more to FTRE or CTKB?

Do institutionals and insiders have more ownership in FTRE or CTKB?

Is FTRE or CTKB more profitable?

Do analysts prefer FTRE or CTKB?

Which has more volatility & risk, FTRE or CTKB?

Summary

How does Cytek Biosciences compare to Personalis?

Is CTKB or PSNL more profitable?

Does the media refer more to CTKB or PSNL?

Do insiders & institutionals have more ownership in CTKB or PSNL?

Which has stronger valuation and earnings, CTKB or PSNL?

Which has more risk & volatility, CTKB or PSNL?

Do analysts prefer CTKB or PSNL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools